Other Events ·
Sanofi announced several regulatory approvals and a key leadership appointment in June 2026
SNYSanofi
Sanofi announced several regulatory approvals and a key leadership appointment in June 2026. Japan approved the subcutaneous formulation of Sarclisa for multiple myeloma patients, and Wayrilz was also approved in Japan for treating immune thrombocytopenia. In the EU, Cenrifki (tolebrutinib) received approval as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses. Additionally, Paulo Fontoura was appointed as the company's Global Head of R&D. Sanofi is a pharmaceutical company that develops and manufactures medicines.